Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Stem cell therapy prevents type 1 diabetes induced by anti-cancer drugs

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

Discovery of novel antibody that targets shared epitope on SARS-CoV-2 variants

Discovery of novel antibody that targets shared epitope on SARS-CoV-2 variants

Study describes ultra-structure of Nipah virus surface glycoprotein

Study describes ultra-structure of Nipah virus surface glycoprotein

Combination therapy shows promise for treating triple-negative breast cancer

Combination therapy shows promise for treating triple-negative breast cancer

Roswell Park experts to share latest advances in the treatment of blood-related cancers

Roswell Park experts to share latest advances in the treatment of blood-related cancers

The impact of leronlimab on CCR5 surface cell levels during long COVID

The impact of leronlimab on CCR5 surface cell levels during long COVID

New data may change the standard of care for patients with advanced non-small cell lung cancer

New data may change the standard of care for patients with advanced non-small cell lung cancer

Monoclonal-antibody combination AZD7442 prevents COVID-19

Monoclonal-antibody combination AZD7442 prevents COVID-19

An abnormally suppressed immune system may be to blame in some cases of long COVID-19

An abnormally suppressed immune system may be to blame in some cases of long COVID-19

Antibody-based treatment, endogenous immune responses, and within-host SARS-CoV-2 evolution in immunocompromised patients

Antibody-based treatment, endogenous immune responses, and within-host SARS-CoV-2 evolution in immunocompromised patients

Investigating the impact of SARS-CoV-2 Omicron spike mutations

Investigating the impact of SARS-CoV-2 Omicron spike mutations

New, longest documented case of persistent acute SARS-CoV-2 infection

New, longest documented case of persistent acute SARS-CoV-2 infection

How the test-to-treat pillar of the US covid strategy is failing patients

How the test-to-treat pillar of the US covid strategy is failing patients

Comparison of neutralizing antibody response following SARS-CoV-2 booster vaccination with breakthrough infection

Comparison of neutralizing antibody response following SARS-CoV-2 booster vaccination with breakthrough infection

Treg cell Notch receptors drive SARS-CoV-2-induced MIS-C

Treg cell Notch receptors drive SARS-CoV-2-induced MIS-C

Decoy nanoparticles could provide a quick, effective treatment for COVID-19

Decoy nanoparticles could provide a quick, effective treatment for COVID-19

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.